ACTI.ST Stock - Active Biotech AB (publ)
Unlock GoAI Insights for ACTI.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $6.72M |
| Gross Profit | $-1,640,000 | $-1,675,000 | $-1,494,000 | $-1,280,000 | $6.72M |
| Gross Margin | N/A | N/A | N/A | N/A | 100.0% |
| Operating Income | $-39,800,000 | $-46,484,000 | $-57,886,000 | $-49,782,000 | $-32,306,000 |
| Net Income | $-39,400,000 | $-45,800,000 | $-58,691,000 | $-49,883,000 | $-32,117,000 |
| Net Margin | N/A | N/A | N/A | N/A | -477.6% |
| EPS | $-0.09 | $-0.17 | $-0.23 | $-0.20 | $-0.19 |
Active Biotech AB (publ), a biotechnology company, develops pharmaceutical products the treatment of oncology and immunology diseases in Sweden. It is developing Tasquinimod, a small molecule immuno-modulator, which is in Phase Ib/IIa clinical trial to treat multiple myeloma; Laquinimod, an immunomodulator that is in phase I clinical trial for the treatment of inflammatory eye disorders, including uveitis; and Naptumomab, an anti-cancer immunotherapy, which is in phase Ib/II clinical trial to treat patients with advanced solid tumors. The company has a licensing agreement with NeoTX Therapeutics Ltd. for the development and commercialization of Naptumomab for cancer immunotherapy. Active Biotech AB (publ) was incorporated in 1983 and is headquartered in Lund, Sweden.
Visit WebsiteEarnings History & Surprises
ACTI.STEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 7, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | — | — | — | — |
Q4 2025 | Nov 6, 2025 | — | $-0.00 | — | — |
Q3 2025 | Aug 21, 2025 | — | $-0.01 | — | — |
Q2 2025 | May 8, 2025 | — | $-0.01 | — | — |
Q1 2025 | Feb 13, 2025 | — | $-0.02 | — | — |
Q4 2024 | Oct 22, 2024 | — | $-0.01 | — | — |
Q3 2024 | Aug 22, 2024 | — | $-0.03 | — | — |
Q2 2024 | May 9, 2024 | — | $-0.03 | — | — |
Q1 2024 | Feb 8, 2024 | — | $-0.04 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.04 | — | — |
Q3 2023 | Aug 24, 2023 | — | $-0.04 | — | — |
Q2 2023 | Apr 26, 2023 | — | $-0.04 | — | — |
Q1 2023 | Feb 9, 2023 | — | $-0.05 | — | — |
Q4 2022 | Nov 3, 2022 | — | $-0.06 | — | — |
Q3 2022 | Aug 4, 2022 | — | $-0.07 | — | — |
Q2 2022 | Apr 21, 2022 | — | $-0.07 | — | — |
Q1 2022 | Feb 10, 2022 | — | $-0.06 | — | — |
Q4 2021 | Nov 4, 2021 | — | $-0.05 | — | — |
Q3 2021 | Aug 5, 2021 | — | $-0.06 | — | — |
Latest News
Frequently Asked Questions about ACTI.ST
What is ACTI.ST's current stock price?
What is the analyst price target for ACTI.ST?
What sector is Active Biotech AB (publ) in?
What is ACTI.ST's market cap?
Does ACTI.ST pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ACTI.ST for comparison